Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study

In comparison to other oral glucose-lowering agents, DPP-4 inhibitor treatment did not increase overall risk of DR. However, DPP-4 inhibitors may be associated with an increased risk of retinopathy events early in the treatment phase.